UCB Biopharma
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels.
At UCB, we believe that everyone deserves to live the best life that they can. That’s why – as a global biopharmaceutical leader - we’re focused on creating valuable solutions that make improvements to the lives of people living with neurological and autoimmune conditions now and into the future.
We work closely and forge strong connections with patients, caregivers, health care professionals and other stakeholders who know the challenges of these diseases and where the unmet needs are found all too well.
UCB’s foundational commitment to crafting valuable solutions and delivering medicines that aim to improve lives is at the core of all that we do, as we live our purpose each day, bringing together the expertise, talent, tools, and scientific ingenuity needed to pursue what’s right for those who live with severe diseases.
Role within Screen4Care
Building on the knowledge gained by working with the neurology and immunology community, UCB is expanding its efforts to develop treatments for rare neurological and immunological diseases where current options offer little hope.
UCB supports a broad approach to rare disease patient needs, working side-by-side with communities and embedding their perspectives in all our activities. This multi-dimensional perspective – underpinned by insights from real patient experiences and other partners - gives UCB insights to address the full range of rare disease patient’s needs. This knowledge, expertise and approach will be brought to S4C to address the multiple needs of rare disease patients & carers.
Specifically, UCB will be in Work Packages (WPs) 1 ,2, 3, 4, 5 and 6 to achieve the objectives of the Screen4Care project.
